NCT05133661 (HPV) is a clinical trial of HPV testing in Cervical Cancer, sponsored by Jhpiego.

Who is sponsoring NCT05133661?

NCT05133661 is sponsored by Jhpiego.

What drugs are being tested in NCT05133661?

Interventions in NCT05133661: HPV testing.

What condition does NCT05133661 study?

NCT05133661 studies Cervical Cancer.

Is NCT05133661 still recruiting?

NCT05133661 is currently active, enrolled. Last updated 17 September 2025.

Last reviewed 2025-09-17 · How we verify

NCT05133661: HPV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SUCCESS - Feasibility of HPV Testing and Treatment of Pre-cancerous Cervical Cancer Lesions (HPV Study)

Active, enrolled Last updated 17 September 2025

What this trial tests

trial testing HPV testing in Cervical Cancer in 17,602 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 April 2022

Primary endpoint
5 September 2025

31 December 2025

Quick facts

Lead sponsor	Jhpiego
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	17,602
Start date	19 April 2022
Primary completion	5 September 2025
Estimated completion	31 December 2025
Sites	4 locations across Philippines, Guatemala, Côte d’Ivoire, Burkina Faso

Drugs / interventions tested

HPV testing

Conditions studied

Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Jhpiego — full company profile →

Who can join

Adults 25 to 49, any sex, with Cervical Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal is to assess the feasibility and acceptability of integrating into existing health systems, provision of HPV screening and treatment of pre-cancerous cervical cancer lesions with ablative treatments in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. Study findings will inform implementation of cervical cancer prevention and treatment services as part of a global effort to eliminate cervical cancer, with particular relevance for low-and-middle income countries. This will inform country strategy and guidelines on offering integrated cervical cancer prevention and treatment services in a manner that is culturally sensitive, client oriented, and system appropriate.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Understanding integrated HPV testing and treatment of pre-cancerous cervical cancer in Burkina Faso, Cote d'Ivoire, Guatemala and Philippines: study protocol.
Kabue M, Gauvreau CL, Daceney N, Bertram MM, et al · · 2023 · cited 2× · PMID 37957689 · DOI 10.1186/s12978-023-01696-8
Understanding Integrated Hpv Testing and Treatment of Pre- Cancerous Cervical Cancer in Burkina Faso, Cote D’Ivoire, Guatemala and Philippines: Study Protocol
Kabue M, Gauvreau CL, Daceney N, Bertram MM, et al · · 2023 · DOI 10.21203/rs.3.rs-2386879/v1

Verify or expand the search:

Other trials of HPV testing

Trials testing the same drug.

NCT06796738 — Advancing Cervical Cancer Screening Through the Emergency Department - IIS · NA · active not recruiting
NCT06906913 — Oral and Anal Swab Sampling in Patients With HPV Positivity · completed
NCT05173324 — Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial · Phase 3 · not yet recruiting
NCT05229679 — HPV-based Screening Among Women 23-29 Years of Age · NA · recruiting
NCT04154358 — Implementing HPV DNA Self-Collection to Increase Rates of Cervical Cancer Screening in Transgender Men · NA · unknown

Other recruiting trials for Cervical Cancer

Currently open trials in the same condition.

NCT07276360 — Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda · Phase 2 · recruiting
NCT05570422 — A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 · Phase 1 · recruiting
NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting

Other Jhpiego trials

Trials by the same sponsor.

NCT06258200 — The Role of Gender Transformative Interventions to Strengthen Gender Equity and Improve Immunization Outcomes · NA · active not recruiting
NCT05774626 — Injectable Contraception Cohort Study in Punjab, Pakistan · completed
NCT05563974 — Family Led Postnatal Care in Ethiopia · NA · completed
NCT05565196 — Birth Companion Intervention in Ethiopia, Kenya and Nigeria · NA · completed
NCT05331508 — Testing Gender-based Violence Response in Family Planning and Antenatal Care Services in Nigeria · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05133661 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jhpiego
Last refreshed: 17 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05133661.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing